Antibody-conjugated nanoparticles for target-specific drug delivery of chemotherapeutics

Scholarly Works

• Panday, A.; Dixena, B.; Vyas, A.; Jain, A. K. Engineered monoclonal antibody nanoconjugates for specifically guided therapies against breast cancer. Chemical Engineering Journal 2025, 524, 169329. doi:10.1016/j.cej.2025.169329
• Tian, L.; Wang, X.; Chen, Y.; Wang, W.; Wu, A.; Jiang, Q.; Zhu, H.; Liu, N.; Pan, J.; Jin, Y. Application of Nano-Drug Delivery Systems in Lung Cancer Diagnosis and Treatment. Biotechnology journal 2025, 20, e70147. doi:10.1002/biot.70147
• Singla, L. Comparative Pathways of Traditional Vaccines and Nanoparticle Innovations in Immunization Science. Progress in Drug Research; Springer Nature Switzerland, 2025; pp 337–362. doi:10.1007/978-3-032-00796-4_12
• Ghilane, F.; El Omari, N.; Goh, K. W.; Bourais, I.; Bakri, Y.; El Btaouri, H.; Bouyahya, A. Mechanistic insights and clinical perspectives on anticancer natural compounds from dietary polyphenols. Journal of Functional Foods 2025, 133, 106991. doi:10.1016/j.jff.2025.106991
• Kaviani, M.; Tayebi-Khorrami, V.; Marami, Y.; Hassanian, S. M. Targeting the PI3K/Akt/mTOR pathway with nanotechnology: A novel therapeutic strategy for gastrointestinal cancers. Nanomedicine : nanotechnology, biology, and medicine 2025, 69, 102861. doi:10.1016/j.nano.2025.102861
• Ka, Y.; Tan, T.; Fan, Y.; Liu, W.; Wang, A.; Wang, W.; Yuzhen, G.; Zhang, J.; Yao, X.; Lin, X.; Wu, Y. STING pathways and Sjögren's syndrome: Exploration from mechanism to treatment. Frontiers in immunology 2025, 16, 1649046. doi:10.3389/fimmu.2025.1649046
• Volpini, C.; Bloise, N.; Casali, C.; Albini, B.; Dominoni, M.; Barra, F.; Biggiogera, M.; Galinetto, P.; Gardella, B.; Vellone, V. G.; Ferrero, S.; Minzioni, P.; Visai, L. AntiCD44 antibody-conjugated gold nanoparticles for targeted photothermal therapy of endometriotic cells. Biomaterials science 2025, 13, 5164–5183. doi:10.1039/d5bm00701a
• Shahapurmath, S.; Sharannavar, B. R.; Koli, R. Serum albumin nanoparticles: Ligand functionalization for enhanced targeted therapeutics in precision medicine. Medicine in Drug Discovery 2025, 27, 100218. doi:10.1016/j.medidd.2025.100218
• Cui, J.; Wang, K.; Wu, Z.; Sun, W.; Gao, T.; Shen, X.; Wang, W.; Cao, Y.; Xue, B. Designing Protein-Based Nanoparticles for Therapeutic Applications. ACS applied materials & interfaces 2025, 17, 50142–50167. doi:10.1021/acsami.5c10918
• Xu, Z.; Xie, Y.; Chen, W.; Deng, W. Nanocarrier-Based Systems for Targeted Delivery: Current Challenges and Future Directions. MedComm 2025, 6, e70337. doi:10.1002/mco2.70337
• Tai, S. S. A.; Loo, H. L.; Bakhtiar, A.; Ho, P. C.-L.; Chuah, L. H. Antibody-conjugated polymer nanoparticles for brain cancer. Drug delivery and translational research 2025, 15, 4367–4410. doi:10.1007/s13346-025-01947-0
• Dixit, T.; Aswini, A.; Nikam, H.; Vaidya, A.; Ravindran, S. Emerging trends in synthesis, characterization, and mechanism of action of antibody-drug and antibody-nanoparticle conjugates. Discover nano 2025, 20, 139. doi:10.1186/s11671-025-04303-w
• Park, S.; Lu, G.-L.; Zheng, Y.-C.; Davison, E. K.; Li, Y. Nanoparticle-Based Delivery Strategies for Combating Drug Resistance in Cancer Therapeutics. Cancers 2025, 17, 2628. doi:10.3390/cancers17162628
• El-Mallul, A.; Tomasiuk, R.; Pieńkowski, T.; Kowalska, M.; Hasan, D.; Kostrzewa, M.; Czerwonka, D.; Sado, A.; Rogowska, W.; Zubrzycki, I. Z.; Wiacek, M. Applications of Nanoparticles in the Diagnosis and Treatment of Ovarian Cancer. Nanomaterials (Basel, Switzerland) 2025, 15, 1200. doi:10.3390/nano15151200
• Gomerdinger, V. F.; Nabar, N.; Hammond, P. T. Advancing engineering design strategies for targeted cancer nanomedicine. Nature reviews. Cancer 2025, 25, 657–683. doi:10.1038/s41568-025-00847-2
• Cakir, N.; Oncel, H.; Ozkan, A.; Bicak, D.; Akgun Bas, S.; Mustafaoglu, N. Developing Immunoniosomes (INs): Antibody and Fab conjugations of niosomal nanoparticles via UV-NBS and EDC/NHS chemistry for treating glioblastoma cells. International journal of pharmaceutics: X 2025, 10, 100367. doi:10.1016/j.ijpx.2025.100367
• Mohamed, H. R. H.; Hakeem, G. M.; Latif, Y. A.; Elnawasani, S. H.; Nagy, M.; Mohamed, B. A.; Essam, R.; Safwat, G. Yttrium oxide nanoparticles induce selective cytotoxicity, genomic instability and ROS mitochondrial P53 mediated apoptosis in human pancreatic cancer cells. Scientific reports 2025, 15, 20144. doi:10.1038/s41598-025-05088-9
• Akbari, B.; Hasan, M. M.; Islam, S. M. Advances in targeted therapy for triple-negative breast cancer: a review of key antigens and recent advances. Journal of drug targeting 2025, 33, 1555–1574. doi:10.1080/1061186x.2025.2520306
• Pacholczak-Madej, R.; Meluch, M.; Püsküllüoğlu, M. Sequencing of antibody drug conjugates in breast cancer: Evidence gap and future directions. Biochimica et biophysica acta. Reviews on cancer 2025, 1880, 189369. doi:10.1016/j.bbcan.2025.189369
• Tasleem, M. W.; Rajpoot, S. R.; Zhang, H. Advances in cancer therapeutics with aptamer-functionalized ZIF-8 formulations for site-specific drug delivery. International journal of pharmaceutics 2025, 681, 125816. doi:10.1016/j.ijpharm.2025.125816

Explore citations to this article at